SLC6A4 STin2 VNTR genetic polymorphism is associated with tobacco use disorder, but not with successful smoking cessation or smoking characteristics: A case control study

BMC Genetics

Volumn 15, Issue , 2014, Pages

  Pizzo de Castro, Márcia R ^a   Maes, Michael ^a,b,c   Guembarovski, Roberta L ^a   Ariza, Carolina B ^a   Reiche, Edna Maria V ^a   Vargas, Heber O ^a   Vargas, Mateus M ^a   de Melo, Luiz Gustavo P ^a   Dodd, Seetal ^b,d,e   Berk, Michael ^b,d,e   Watanabe, Maria Angelica E ^a   Nunes, Sandra Odebrecht V ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b DEAKIN UNIVERSITY   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e BARWON HEALTH   (Australia)

Author keywords

Genetic; Inflammation; Oxidative stress; Polymorphism; Serotonin; Smoking cessation; STin2 VNTR; Tobacco use disorder

Indexed keywords

AMFEBUTAMONE; CARBON MONOXIDE; SEDATIVE AGENT; ALCOHOL; SEROTONIN TRANSPORTER;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CASE CONTROL STUDY; COGNITIVE THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; DSM-IV; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NICOTINE REPLACEMENT THERAPY; ONSET AGE; PSYCHOLOGICAL RATING SCALE; RISK FACTOR; SMOKING CESSATION; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT DURATION; VARIABLE NUMBER OF TANDEM REPEAT; ALLELE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE ASSOCIATION; DISEASE DURATION; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; PSYCHOPHARMACOTHERAPY; RISK ASSESSMENT; SMOKING; STIN2 GENE; SUBSTANCE USE; TOBACCO USE; TREATMENT RESPONSE;

NICOTIANA TABACUM;

ADULT; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 84904981404     PISSN: None     EISSN: 14712156     Source Type: Journal    
DOI: 10.1186/1471-2156-15-78     Document Type: Article

References (57)

1. Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking 2000. Lancet 2003, 362:847-852.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray C. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757.
3. Belsky D, Moffitt T, Baker T, Biddlem A, Evans J, Harrington H, Houts R, Meier M, Sugden K, Williams B, Poulton R, Caspi A. Polygenic risk and the developmental progression to heavy, persistent smoking and nicotine dependence. JAMA Psychiatry 2013, 70(5):534-542.
4. Centers for Disease Control and Prevention (CDC) Quitting smoking among adults: United States, 2001-2010. Morb Mortal Wkly Rep 2011, 60(44):1513-1519. Centers for Disease Control and Prevention (CDC).
5. American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-5 2013, Washington, DC: Author, American Psychiatric Publishing, 5, American Psychiatric Association.
6. Serretti A, Calati R, Mandelli L, De Ronchi D. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 2006, 7:1659-1669.
7. Alves de Lima K, Guembarovski R, Oda J, Ramos G, Oliveira B, Cavalli I, Ribeiro E, Gonçalves M, Aoki M, Nunes SOV, Watanabe MAE. Association between the STin2 VNTR polymorphism and smoking behavior in oral cancer patients and healthy individuals. Clin Exp Med 2012, 12:13-19.
8. Brody LC, Hamer HD, Haaga DAF. Depression vulnerability, cigarette smoking, and the serotonin transporter gene. Addict Behav 2005, 30:557-566.
9. Tsuang MT, Francis T, Minor K, Thomas A, Stone WS. Genetics of smoking and depression. Hum Genet 2012, 131(6):905-915.
10. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, Mc Clay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
11. Lerman C, Caparaso N, Audrain J, Main D, Boyd N, Shields P. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol Psychiatry 2000, 5:189-192.
12. Lerman C, Shields P, Audrain J, Main D, Cobb B, Boyd N, Caparaso N. The role of the serotonin transporter gene in cigarette smoking. Cancer Epidemiol Biomarkers Prev 1998, 7:253-255.
13. Ishikawa H, Ohtsuki T, Ishiguro H, Yamakawa-Kobayashi K, Endo K, Lin Y-L, Yanagi H, Tsuchiya S, Kawata K-I, Hamaguchi H, Arinami T. Association between serotonin transporter gene polymorphism and smoking japonese males. Cancer Epidemiol Biomarkers Prev 1999, 8:831-833.
14. Hu S, Brody CL, Fisher C, Gunzerath L, Nelson ML, Sabol SZ, Sirota LA, Marcus SE, Greenberg BD, Murphy DL, Hamer DH. Interaction between the serotonin transporter gene and neuroticism in cigarette smoking behavior. Mol Psychiatry 2000, 5(2):181-188.
15. Nunes SOV, De Castro MRP, Vargas HO, Vargas MM, Bueno RRM, Fonseca ICB, Dodd S, Berk M. Clinical characteristics and smoking cessation: an analysis of sex and depressive disorders differences. Addict Disord Their Treat 2013, 12(3):158-165.
16. Munafò MR, Johnstone EC, Mackintosh B. Association of serotonin transporter genotype with selective processing of smoking-related stimuli in current smokers and ex-smokers. Nicotine Tob Res 2005, 7(5):773-778.
17. Munafò MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol Biomarkers Prev 2006, 15(2):398-400.
18. Skowronek MH, Laucht M, Hohm E, Becker K, Schmidt M. Interaction between the dopamine D4 receptor and the serotonin transporter promoter polymorphisms in alcohol and tobacco use among 15-year- olds. Neurogenetics 2006, 7:239-246.
19. Trummer O, Köppel H, Wascher TC, Grünbacher G, Gutjahr M, Stanger O, Ramschak-Schwarzer S, Boehm BO, Winkelmann BR, März W, Renner W. The serotonin transporter gene polymorphism is not associated with smoking behavior. Pharmacogenomics J 2006, 6:397-400.
20. David SP, Munafò MR, Murphy MFG, Walton RT, Johnstone EC. The serotonin transporter 5- HTTLPR polymorphism and treatment response to nicotine patch: Follow-up of a randomized controlled trial. Nicotine Tob Res 2007, 9(2):225-231.
21. Han D-H, Joe K-H, Na C, Lee Y-S. Effect of genetic polymorphisms on smoking cessation: a trial of bupropion in korean male smokers. Psychiatr Genet 2008, 18:11-16.
22. Sieminska A, Buczkowski K, Jassen E, Tkacz E. Lack of association between serotonin transporter gene polymorphism 5- HTTLPR and smoking among Polish population: a case-control study. BMC Med Genet 2008, 9:76.
23. Watanabe MAE, Nunes SOV, Amarante MK, Guembarovski RL, Oda JMM, Lima KWAD, Fungaro MHP. Genetic polymorphism of serotonin transporter 5-HTTLPR: involvement in smoking behaviour. J Genet 2011, 90:179-185.
24. Ishii T, Wakabayashi R, Kurosaki H, Gemma A, Kida K. Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms. Am J Hum Genet 2011, 56:41-46.
25. Yang Z, Seneviratne C, Wang S, Ma JZ, Payene TJ, Wang J, Li MD. Serotonin transporter and receptor genes significantly impact nicotine dependence through genetic interactions in both european american and african smokers. Drug Alcohol Depend 2013, 129:217-225.
26. Kremmer I, Bachner-Melman R, Reshef A, Broude L, Nemanov L, Gritsenko I, Heresco-Levy U, Elizur Y, Ebstein RP. Association of the serotonin transporter gene with smoking behavior. Am J Psychiatry 2005, 162(5):924-930.
27. Mrazek DA. Psychiatric Pharmacogenomics 2010, New York: Oxford University Press.
28. Herman A, Balogh K. Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse. Subst Abuse Rehabil 2012, 20(2-3):49-57.
29. Iordanidou M, Tavridou A, Petridis I, Kyroglou S, Kaklamanis L, Christakidis D, Manolopoulos VG. Association of polymorphisms of the serotonergic system with smoking initiation in Caucasians. Drug Alcohol Depend 2010, 108:70-76.
30. Sarosi A, Gonda X, Balogh G, Domotor E, Szekely A, Hejjas K, Sasvari-Szekely M, Faludi G. Association of the STin2 polymorphism of the serotonin transporter gene with a neurocognitive endophenotype in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1667-1672.
31. Fan JB, Scalar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia. Mol Psychiatry 2005, 10:928-938.
32. Castro MRP, Matsuo T, Nunes SOV. Clinical characteristics and quality of life of smokers at a referral center for smoking cessation. J Bras Pneumol 2010, 36(1):67-74.
33. Castro MRP, Matsuo T, Nunes SOV. Characteristics of smokers in smoking cessation interventions: an analysis of sex differences. Addict Disord Their Treat 2010, 9(4):135-142.
34. Nunes SOV, Vargas HO, Brum J, Prado E, Vargas MM, De Castro MRP, Dodd S, Berk M. A comparison of inflammatory markers in depressed and non-depressed smokers. Nicotine Tob Res 2012, 14:540-546.
35. Vargas HO, Nunes SOV, De Castro MRP, Bortolasci CC, Barbosa DS, Morimoto HK, Venugopal K, Dodd S, Maes M, Berk M. Oxidative stress and lowered total antioxidant status are associated with history of suicide attempts. J Affect Disorders in press.
36. Vargas HO, Nunes SOV, De Castro MRP, Vargas MM, Barbosa DS, Bortolasci CC, Venugopal K, Dodd S, Berk M. Oxidative stress and inflammatory markers are associated with depression and nicotine dependence. Neurosci Lett 2013, 544:136-140.
37. Malone KM, Waternaux C, Haas GL, Cooper TB, Li S, Mann JJ. Cigarette smoking, suicidal behavior, and serotonin function in major psychiatric disorders. Am J Psychiatry 2003, 160:773-779.
38. Bah J, Lindström M, Westberg L, Mannerås L, Ryding E, Henningsson S, Melke J, Rosén I, Träskman-Bendz L, Erikson E. Serotonin transporter gene polymorphisms: effects on serotonin transporter availability in the brain of suicide attempters. Psychiatry Res 2008, 162:221-229.
39. Quaak M, Schayck CP, Knaapen AM, Schooten F. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases?. Eur Respir J 2009, 33:468-480.
40. Del Ben CM, Vilela JAA, Crippa JAS, Hallak JEC, Labate CM, Zuardi AW. Confiabilidade da " entrevista clinica estruturada para o DSM-IV" - versão clínica traduzida para o português. Rev Bras Psiquiatr 2001, 23(3):156-159.
41. Centers for Disease Control and Prevention (CDC) Cigarette smoking in the United States: current cigarette smoking among U.S. adults aged 18 years and older. 2009, http://www.cdc.gov/tobacco/campaign/tips/resources/data/cigarette-smoking-in-united-states.html, Centers for Disease Control and Prevention (CDC).
42. Fagerström KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerström Tolerance Questionnaire. J Behav Med 1989, 12:159-182.
43. Carmo JT, Pueyo AA. A adaptação ao português do Fagerström Test for Nicotine Dependence (FTND) para avaliar a dependência e tolerância à nicotina em fumantes. Rev Bras Med 2002, 59(1/2):73-80.
44. Reichert J, Araújo AJ, Gonçalves CMC, Godoy I, Chatkin JM, Sales MPU, Santos SRR SRR. Diretrizes para cessação do tabagismo - 2008. Smoking cessation guidelines - 2008. J Bras Pneumol 2008, 34(10):845-880.
45. Middleton ET, Morice AH. Breath carbon monoxide as an indication of smoking habit. Chest 2000, 117(3):758-763.
46. Ministério da Saúde (Brasil) Secretaria de Atenção à Saúde, Portaria SAS/MS 442/04 de 13 de agosto de 2004. Aprova o Plano de Implantação da Abordagem e Tratamento do Tabagismo no SUS. D.O.U n° 158 17/08/2004 Brasília, DF, Retrieved from: http://dtr2001.saude.gov.br/sas/PORTARIAS/Port2004/PT-442.htm, Ministério da Saúde (Brasil).
47. Nunes SOV, Vargas HO, Castro MR, Machado RCB, Carmo DR. Abordagem intensiva. Abordagem, Prevenção e Tratamento do Tabagismo 2011, 97-216. Londrina: Eduel, Nunes SOV, Castro MRP.
48. World Health Organization (WHO) The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002, 97(9):1183-1194. World Health Organization (WHO).
49. Keskitalo K, Broms U, Heliövaara M, Ripatti S, Surakka I, Perola M, Pitkäniemi J, Peltonen L, Aromaa A, Kaprio J. Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. Hum Mol Genet 2009, 18:4007-4012.
50. The Tobacco and Genetics Consortium Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet 2010, 42(5):441-447. The Tobacco and Genetics Consortium.
51. Lessov-Schlaggar CN, Pergadia ML, Khroyan TV, Swan GE. Genetics of nicotine dependence and pharmacotherapy. Biochem Pharmacol 2008, 75:178-195.
52. O'Loughlin J, DiFranza J, Tyndale RF, Meshefedjian G, McMillan-Davey E, Clarke PB, Hanley J, Paradis G. Nicotine-dependence symptoms are associated with smoking frequency in adolescents. Am J Prev Med 2003, 25(3):219-225.
53. Hernandez-Lopez S, Garduño J, Mihailescu S. Nicotinic modulation of serotonergic activity in the dorsal raphe nucleus. Rev Neurosci 2013, 24:455-469.
54. Hughes JR. Smoking and suicide: a brief overview. Drug Alcohol Depend 2008, 98:169-178.
55. Ho P-S, Ho KK-J, Huang W-S, Yen C-H, Shih M-C, Shen L-H, Ma K-H, Huang S-Y. Association study of serotonin transporter availability and SLC6A4 gene polymorphisms in patients with major depression. Psychiatry Res 2013, 212:216-222.
56. Maes M, Chang YS, Galecki P, Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:676-692.
57. Nunes SOV, Vargas HO, Prado E, Barbosa DS, Melo LP, Moylan S, Dodd S, Berk M. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev 2013, 37:1336-1345.